Your Health, We Care
Release date: 2026-01-23 16:38:07 Article From: Lucius Laos Recommended: 12
The monthly treatment cost of lorlatinib currently available in China fluctuates according to specifications and regional differences, and may change in the future with the adjustment of the national medical insurance catalog or the launch of generic drugs.
The exact price of lorlatinib in 2026 cannot be accurately predicted at present, as its actual cost is affected by multiple factors such as medical insurance policies, market supply, and drug price negotiations.
If lorlatinib is included in the national or local medical insurance catalog, the out-of-pocket expenses for patients may be significantly reduced. For example, in 2023, the prices of some anti-cancer drugs were cut by more than 50% through medical insurance negotiations.
It is recommended to pay close attention to the updates of the medical insurance catalog during 2024-2025, and obtain the latest reimbursement rates through hospitals or medical insurance authorities.
The price may drop further if lorlatinib is included in the volume-based procurement of drugs.
After the expiration of the original drug patent (expected around 2025), the launch of generic drugs may trigger price competition.
Some pharmaceutical companies or charitable organizations offer patient assistance programs to alleviate the financial burden on patients.
Commercial insurance plans (e.g., universal medical insurance schemes for urban and rural residents) may cover part of the expenses, and patients are advised to consult the insurance providers for details.
Lorlatinib is a prescription drug and must be used strictly under the guidance of a physician. Regular monitoring for adverse reactions (e.g., hypercholesterolemia, edema) is required.
It is recommended to obtain the drug through formal medical institutions and avoid purchasing it from unauthorized channels, so as to ensure the quality of the drug and the safety of medication.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3652024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：792025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：892025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：922025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
